VolitionRx (VNRX) - First product ready to enter market

08:20 EDT 23 Sep 2016 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - VolitionRx: VolitionRx is a developer of blood-based diagnostics for cancer that detect the quantity and composition of cell-free nucleosomes (a complex of protein and DNA) present in the blood. The company announced its first commercial product, the NuQ triage colorectal cancer test, will launch in select European countries in early 2017. The product is not a diagnostic test, but is designed to reduce the number of colonoscopies by screening false positives from fecal immunochemical tests (FIT).
ISIN: US9286611077

Original Article: VolitionRx (VNRX) - First product ready to enter market


More From BioPortfolio on "VolitionRx (VNRX) - First product ready to enter market"

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...